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A B S T R A C T
While conventional parameters used to detect hepatotoxicity in drug safety assessment studies are
generally informative, the need remains for parameters that can detect the potential for hepatotoxicity at
lower doses and/or at earlier time points. Previous work has shown that metabolite proﬁling
(metabonomics/metabolomics) can detect signals of potential hepatotoxicity in rats treated with
doxorubicin at doses that do not elicit hepatotoxicity as monitored with conventional parameters. The
current study extended this observation to the question of whether such signals could be detected in rats
treated with compounds that can elicit hepatotoxicity in humans (i.e., drug-induced liver injury, DILI) but
have not been reported to do so in rats. Nine compounds were selected on the basis of their known DILI
potential, with six other compounds chosen as negative for DILI potential. A database of rat plasma
metabolite proﬁles, MetaMap1Tox (developed by metanomics GmbH and BASF SE) was used for both
metabolite proﬁles and mode of action (MoA) metabolite signatures for a number of known toxicities.
Eight of the nine compounds with DILI potential elicited metabolite proﬁles that matched with MoA
patterns of various rat liver toxicities, including cholestasis, oxidative stress, acetaminophen-type
toxicity and peroxisome proliferation. By contrast, only one of the six non-DILI compounds showed a
weak match with rat liver toxicity. These results suggest that metabolite proﬁling may indeed have
promise to detect signals of hepatotoxicity in rats treated with compounds having DILI potential.
ã 2014 Elsevier Ireland Ltd. All rights reserved.
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The clear goal of safety evaluation studies is to characterize the
hazards posed by a novel chemical. This goal (hazard characteri-
zation) is well established for human and environmental risk
assessment (Faustman and Omenn, 2008) and drug development
(ICH Steering Committee, 2009). Because overt toxicity is preceded
by a complex sequence of biochemical, cellular and physiological
events (Gregus, 2008), exposures to novel chemicals are evaluated
with a variety of parameters that monitor these events (Baldrick,* Corresponding author. Tel.: +49 621 56419.
E-mail address: bennard.ravenzwaay@basf.com (B. van Ravenzwaay).
http://dx.doi.org/10.1016/j.toxlet.2014.07.021
0378-4274/ã 2014 Elsevier Ireland Ltd. All rights reserved.2008; Crissman et al., 2004; ICH Steering Committee, 2009;
Weingand et al., 1996). Furthermore, multiple parameters need
to be considered to evaluate the sequence of events leading up to
any given organ toxicity. For example, increases in the blood levels
of alanine aminotransferase (ALT) may presage clear liver
histopathology and failure (Ennulat et al., 2010; Senior, 2009;
Travlos et al., 1996).
An organ toxicity that remains of critical interest to drug
development is that of hepatotoxicity (Corsini et al., 2012; Horner
et al., 2013). Current preclinical safety assessment study designs
and parameters are effective for identifying a large number of
chemicals with hepatotoxic potential, yet examples still exist of
drugs that reach the marketplace only to then elicit cases of
drug-induced liver injury (DILI), i.e., hepatotoxicity (Peters, 2005).
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pathological expressions, due to different mechanisms (Jaeschke
et al., 2002; Russmann et al., 2009), and the molecular events in
microcystin (Campos and Vasconcelos, 2010) and acetaminophen
(Jaeschke et al., 2012) hepatotoxicity point to the complexity in the
sequence of events leading to liver toxicity. Accordingly, research
continues to seek new parameters that will monitor early events in
hepatotoxicity to aid in liver safety assessment (Antoine et al.,
2009).
New discoveries and technologies often offer new parameters
that may complement those conventionally used in existing
testing strategies. Ideally such new parameters ﬁll gaps in
evaluating the multiple events leading to toxicity, particularly in
the ability to monitor early events in the sequence leading up to
overt toxicity. Such parameters would be expected to provide
signals at lower doses and/or earlier time points than provided
by conventional parameters (that may be monitoring events later
in the sequence). As an example, Kim 1 was discovered as a protein
detectable in urine following kidney injury and has been
recognized as detecting nascent nephrotoxicity undetectable by
conventional clinical pathology (Vaidya et al., 2010). Such signalsFig. 1. An overview of the sequence of events following toxicant exposure.
Unique biochemical changes, reﬂected in metabolite proﬁles, may be expected at mul
(Gregus, 2008).from the novel parameters in essence “predict” the signals (i.e., the
toxicity) detected “later” by conventional parameters.
1.1. Metabolite proﬁling
One promising new technology that offers new parameters is
that of metabolite proﬁling (metabonomics/metabolomics), the
measurement in biological systems of the full complement of
endogenous low-molecular-weight metabolites and their inter-
mediates. Several technologies allow such a measurement from
urine, plasma, or tissue extracts. This can offer a global view of the
comprehensive metabolic response of a biological system to
genetic or environmental modiﬁcation (Clarke and Haselden,
2008). If such metabolic responses are occurring early in the
sequence of events leading up to overt toxicity (Fig. 1), they could
be used to detect the adverse potential of chemicals at an early
stage in their development (Beger et al., 2010; van Ravenzwaay
et al., 2012). Indeed, urine metabolites have been shown to detect
cardiotoxicity, hepatotoxicity and nephrotoxicity induced by
doxorubicin treatment at lower doses and earlier time points
than conventional parameters (Wang et al., 2009). Similarly, urinetiple stages in the sequence of events following toxicant exposure. Adapted from
Table 1
Compounds used, dose levels and routes of administration.
Treatment Dose Route
Phenytoin 2400 PPM Diet
Flutamide 100 mg/kg/day po
Propylthiouracil 10 mg/kg/day po
Methotrexate 1 mg/kg/day ip
Captopril 20 mg/kg/day po
Captopril 200 mg/kg/day po
Nefazodone hydrochloride 300 mg/kg/day po
Nevirapine 40 mg/kg/day po
Valproic acid 500 mg/kg/day po
Zidovudine 1000 mg/kg/day po
Atropine sulfate monohydrate 62.5 mg/kg/day po
Mannitol 50000 PPM Diet
Neomycin sulfate 250 mg/kg/day po
Streptomycin sulfate 360 mg/kg/day sc
Vancomycin hydrochloride 200 mg/kg/day ip
Lamivudine 300 mg/kg/day po
po: oral administration by gavage, ip: intraperitoneal injection, sc: subcutaneous
injection, diet: administration in feed.
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treatment with a variety of agents at doses that only elicited signals
of nephrotoxicity after 28 days of treatment as monitored with
conventional parameters (Boudonck et al., 2009).
To explore this capability, the MetaMap1Tox database was
developed by Metanomics Health and BASF’s department for
Experimental Toxicology to augment safety evaluation studies by
adding metabolomic parameters. It represents a unique compen-
dium of plasma metabolite proﬁles from rat studies using over 500
chemicals and drugs with well understood safety proﬁles and/or
biochemical effects. Metabolite proﬁles common to chemicals
sharing common toxicities or effects were used to create
mechanistically based metabolite signatures that then can serve
as parameters to augment conventional parameters in safety
evaluation. A match of a metabolite proﬁle to such signatures
indicates a positive signal for that mode of action (MoA).
In previous work we examined doxorubicin, at 2 mg/kg sc
weekly for 4 weeks, and while clinical chemistry showed no
evidence of hepatotoxicity, plasma metabolic proﬁles of treated
rats showed matches to MoA metabolite signatures indicative of
liver toxicity (Mattes et al., 2013). On the other hand, doxorubicin
has been clearly shown to elicit hepatotoxicity in rats at higher
doses (Deepa and Varalakshmi, 2003; El-Sayyad et al., 2009;
Yagmurca et al., 2007), indicating the capability of metabolomics to
provide signals of rodent hepatotoxicity at doses lower than those
required to elicit signals with conventional parameters. In our
earlier work we have shown, that metabolomics allows for the
identiﬁcation of hepatotoxic effects of compounds known to have
this property in rats as well as humans. This was demonstrated for
“classical” chemicals such as carbon tetrachloride, or pharma-
ceuticals such as paracetamol (van Ravenzwaay et al., 2010). The
purpose of the present study was to investigate if this technology is
sufﬁciently sensitive to pick up signals of hepatotoxicity in rats
treated with compounds that do not show pathological changes in
the liver of rats but are known to elicit such toxicity in humans
(so-called human DILI compounds). Therefore, the selection of
compounds was based on the publication by Chen et al. (2011). As a
control, the metabolite proﬁles of rats treated with compounds
that have not been associated with either rodent or human toxicity
were also examined. In order to avoid additional animal testing,
the evaluations were conducted for compounds that were already
in the data base MetaMap1Tox. The results in this study suggest
that metabolite signatures can indeed indicate signals of hepato-
toxicity even with compounds that do not ultimately elicit signals
of such injury by conventional parameters.
2. Methods
2.1. Compound selection
Fifteen compounds were selected on the basis of existing data
in the MetaMap1Tox database and their classiﬁcation by Chen
et al. (Chen et al., 2011), who used FDA labeling: phenytoin,
ﬂutamide, propylthiouracil, lamivudine, methotrexate, captopril,
nefazodone, nevirapine, valproic acid, and zidovudine were
classiﬁed as having “Most DILI Concern,” while atropine, mannitol,
neomycin, streptomycin, and vancomycin were classiﬁed as having
“No DILI Concern.” These classiﬁcations were subsequently
conﬁrmed by reports in the LiverToxTM database (Hoofnagle
et al., 2013) as well as extensive searching for literature reports
of DILI associated with the drug’s use. In the case of lamivudine
the FDA warning label was, in fact, a warning for the class of
nucleoside anti-retrovirals. No literature report could be found of
hepatotoxicity due to the use of lamivudine alone, consistent with
the conclusions in the LiverToxTM database, and therefore it was
re-classiﬁed for this study having “No DILI Concern.” None of theﬁfteen compounds has been used to establish the patterns for liver
toxicity (see Section 2.4).
2.2. Ethics statement
The studies were approved by the BASF Animal Welfare
Body, and were performed according to the German Animal
Welfare Act and EU Directive 2010/63, with the permission of the
local authority, the Landesuntersuchungsamt Rheinland-Pfalz
(permission number 23 177-07/G08-3-001). The laboratory
is AAALAC (Association for Assessment and Accreditation of
Laboratory Animal Care International) certiﬁed.
2.3. Animal treatment, examinations, clinical pathology and
histopathology
Animal handling, compound treatment, clinical examinations,
and clinical pathology (hematology and clinical chemistry) have
been described earlier (Kamp et al., 2012; van Ravenzwaay et al.,
2007, 2012). Brieﬂy, Wistar rats (CrI:WI(Han)) were supplied by
Charles River, Germany and were approx. 70 days old at the
beginning of the studies. The diet and drinking water were
available ad libitum (except before blood sampling) and regularly
assayed for chemical contaminants and the presence of micro-
organisms. Compound dose-levels and routes of administration
(based on literature and range-ﬁnding data) are summarized in
Table 1. While all studies incorporated a control, low dose level,
and high dose level for each compound, results for captopril are
focused on only the low dose treatment in this report. All animals
were checked daily for mortality and clinical signs. Food
consumption was determined on study days 7, 14, 21 and 28.
Body weight was determined before the start of the administration
period in order to randomize the animals and on study days 0, 4, 7,
14, 21 and 28. At the end of the treatment period, the animals were
sacriﬁced by decapitation under isoﬂurane anesthesia. For all
compounds, clinical pathology (hematology and clinical chemis-
try) was performed on blood collected at sacriﬁce from 5 animals
of each sex in control, low dose, and high dose groups. For 12
(phenytoin, captopril, nefazodone, nevirapine, valproic acid,
zidovudine, atropine, lamivudine, mannitol, neomycin, strepto-
mycin, or vancomycin) of the compounds, liver was collected at
necropsy and ﬁxed in 10% neutral buffered formalin from 5 animals
of each sex in control and high dose groups. After ﬁxation, liver
tissues were processed to hematoxylin and eosin stained glass
slides as described previously (Kamp et al., 2012) and examined by
light microscopy.
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As described by Kamp et al. (Kamp et al., 2012), K-EDTA samples
were taken from the retro-orbital sinus in all rats under isoﬂurane
anesthesia on study days 7, 14 and 28 for mass spectrometry-based
metabolite proﬁling analysis and extracted by a proprietary
method. Two types of mass spectrometry-based metabolite
proﬁling analysis were applied to all samples: GC–MS (gas
chromatography–mass spectrometry) and LC–MS/MS (liquid
chromatography–MS/MS) were used for broad proﬁling and
hormone measurement as described in van Ravenzwaay et al.
(van Ravenzwaay et al., 2007). The method resulted in 225
semi-quantitative analytes, 171 of which are chemically identiﬁed
and 54 are structurally unknown. The changes in these analytes
induced by the various treatments are given in the Supporting
Table.
MetaMap1Tox is a unique database of biochemical proﬁles
from rat plasma and comprehensive pharmacological and toxico-
logical data based on more than 500 pharmaceuticals, chemicals
and agrochemicals after 7, 14 and 28 days of test substance
treatment. Studies used groups of Crl:WI (Han) rats, 5 of each sex in
control, low dose, and high dose groups. Discriminating metabolite
patterns for various toxicological modes of action (MoAs) were
developed from the metabolite proﬁles in the MetaMap1Tox
database (van Ravenzwaay et al., 2012). Brieﬂy, these metabolite
patterns are usually based on the data from at least three
different chemicals included in the MetaMap1Tox database and
which share a common toxicological mode of action (reference
compounds). The establishment of a speciﬁc metabolite pattern
associated with a particular MoA or form of toxicity starts with the
identiﬁcation of common metabolite changes for these reference
compounds. Iteratively, the resulting list of metabolites is checked
for consistency and modiﬁed based on mechanistic knowledge by
an expert panel of experienced toxicologists. During this process
metabolites might be added or removed from the pattern, as well
as given special weight according to the importance for the
predictivity of the pattern. Finally, the resulting pattern is checked
for sensitivity and selectivity against the reference data in theTable 2
Signiﬁcant food consumption, body weight, clinical pathology and histopathology resu
Treatment Summary ﬁndings
Flutamide Decreased body weights in males and decreased food con
Propylthiouracil Decreased body weights and decreased food consumption
Methotrexate Decreased body weights in females and decreased food co
treatment
Captopril (high dose) Slightly decreased creatinine levels in both males and fem
Nefazodone
hydrochloride
Increased inorganic phosphate and white blood cell counts
and females
Nevirapine Increased cholesterol, triglycerides and total protein in fem
Valproic acid Decreased food consumption, globulin, hemoglobin, platel
increased triglycerides and slightly increased inorganic phos
Zidovudine Increased cholesterol and slightly increased mean corpusc
slightly decreased hematocrit, hemoglobin, and red blood c
in males and white blood cell counts in females
Atropine sulfate
monohydrate
Slightly increased total bilirubin (1.4) in males and fema
males; increased triglycerides and inorganic phosphate and
Mannitol Slightly increased total bilirubin (1.2) in males; slightly inc
in females
Neomycin sulfate Increased cholesterol and slightly increased inorganic phosp
in males and females; decreased magnesium in females
Streptomycin sulfate Slightly increased inorganic phosphate and urea in males an
females
Lamivudine Slightly increased platelets in males; decreased food consu
cell counts and slightly decreased total bilirubin (0.7) in
Vancomycin
hydrochloride
Decreased food consumption in males and females; increas
alkaline phosphatase in males; slightly increased inorgani
Microscopic ﬁnding of mild to moderate chronic-active in
peritonitis from intraperitoneal administration of the compdatabase: a pattern should correctly identify at least one further
reference compound sharing the same mode of action, which has
not been used to establish the pattern. Furthermore, reference
compounds in MetaMap1Tox which do not share this particular
toxicity should not be identiﬁed.
The pattern ranking itself is a two-step process. Firstly, an
algorithm used in the database yields a ranking list based on
similarity of the test compound metabolic proﬁle compared to the
speciﬁc patterns in MetaMap1Tox using a median r value metric.
Secondly, the metabolite changes are evaluated by an expert panel
of experienced toxicologists to determine what may be described
as “conﬁrmed” matches. Generally, based on the number of
commonly changed metabolites, a match prerequisites approx.
90% or more of metabolites signiﬁcantly changed as deﬁned by
the pattern (weak matches: approx. 75–90%; equivocal ﬁndings:
approx. 50–75%; mismatches: <50%). Furthermore, the quality and
importance of the metabolite changes for a certain toxicological
mode of action is considered for this evaluation. For example,
metabolites which are based on perturbations of speciﬁc
biochemical pathways, and which can be connected to the toxicity
observed, are particularly evaluated. For some patterns, we have
deﬁned so-called “anchor metabolites”, these metabolites are
essential components of the biochemical pathway related to the
mode of action, and these have to be signiﬁcantly changed in the
right direction in order to result in a matching pattern. The second
step of the process can then result in a determination that a pattern
with a seemingly high median r value may not be considered a
conﬁrmed match.
3. Results
3.1. Food consumption, body weight, clinical pathology and
histopathology
Results of our studies with phenytoin have already been
reported (Kamp et al., 2012); brieﬂy, the high dose treatment with
phenytoin produced statistically signiﬁcant body weight decreases
in both sexes, along with the microscopic ﬁndings of minimal tolts.
sumption in both males and females
 in both males and females
nsumption in both males and females; males were sacriﬁced after 14 days of
ales; increased serum GGT in males
 in females; increased BUN in males; slightly increased magnesium in both males
ales; slightly increased platelets in females; decreased white blood cells in males
ets, red blood cell counts, white blood cell counts in both males and females;
phate and total bilirubin (1.29 and 1.21 respectively) in both males and females
ular hemoglobin content, and mean corpuscular volume, in males and females;
ell counts in males and females; slightly increased urea and total bilirubin (1.42)
les; increased urea in males; decreased food consumption and body weights in
 slightly increased ALT (1.3) in females; decreased urinary creatinine in females
reased ALT (1.23) in females; decreased food consumption and urinary creatinine
hate in males and females; decreased food consumption and alkaline phosphatase
d females; increased triglycerides and slightly increased white blood cell counts in
mption, body weights, and alkaline phosphatase in males; decreased white blood
 females
ed triglycerides and urea in males; decreased body weights and slightly decreased
c phosphate in females.
ﬂammation conﬁned to the hepatic capsule in males and females attributed to
ound without compound-related microscopic ﬁndings in the hepatic parenchyma.
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statistically signiﬁcant changes elicited by the other compounds is
given in Table 2. Mild or modest changes in food consumption,
body weight, clinical chemistry, and/or hematological parameters
were seen in all studies. Parameters suggestive of liver injury
(i.e., elevated ALT, AST or total bilirubin) were unchanged in most of
these studies; serum ALT levels were very slightly, albeit
statistically signiﬁcantly, increased (1.2–1.3 fold) in the atropine
and mannitol studies, while total bilirubin was slightly increased
(1.2–1.4 fold) in the valproic acid, zidovudine, atropine and
mannitol studies. The microscopic ﬁnding of mild to moderate
chronic-active inﬂammation conﬁned to the hepatic capsule was
considered to be related to the high dose administration of
vancomycin in both sexes. The ﬁnding was present in all high dose
vancomycin treated male and female animals and absent in all
male and female control animals. The inﬂammation of the hepatic
capsule was consistent with peritonitis and was considered to be
the result of the intraperitoneal administration of the compound.
There were no microscopic ﬁndings involving the hepatic
parenchyma that were considered related to the high dose
administration of vancomycin. Similarly for the high doseFig. 2. Ranking of patterns matching the metabolite changes induced by ﬂutamide treatm
referred to the web version of this article.)
Based on similarity analysis comparing the metabolic proﬁle produced by ﬂutamide tre
algorithm produces an r value metric. The shaded boxes indicate the subsequent expert a
light green – weak match, yellow – equivocal match (no conclusion possible), red – coadministration of captopril, nefazodone, nevirapine, valproic acid,
zidovudine, atropine, lamivudine, mannitol, neomycin, and
streptomycin there were no microscopic ﬁndings in the liver that
were considered to be treatment related.
3.2. Metabolomic data
Comparison of the metabolite proﬁles of the ﬁfteen compounds
to the MetaMap1Tox database resulted in matches to a number of
validated patterns corresponding to various toxicological and
pharmacological modes of action (MoAs). Results for phenytoin
have been reported earlier (Kamp et al., 2012), where the high-
dose phenytoin resulted in a metabolic proﬁle matching numerous
database patterns associated with liver enzyme induction, liver cell
cytotoxicity, liver cell oxidative stress (i.e., paracetamol-like liver
toxicity), liver cholestasis as well as those associated with indirect
effects on the thryroid due to increased conjugation and excretion
of thyroxin. Human hepatoxicity of phenytoin has been known for
some time (Russo et al., 2004; Smythe and Umstead, 1989), but it
should be noted that in the current study the strong metabolomic
data elicited by phenytoin treatment of rats is accompanied by onlyent. (For interpretation of the references to color in this ﬁgure legend, the reader is
atment with the mode of action (MoA) proﬁles in the MetaMap1Tox database; the
ssessment of the match with the respective pattern: solid green – conﬁrmed match,
nﬁrmed non-match.
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centrilobular hepatocellular hypertrophy).
The high dose ﬂutamide treatment (a non-steroidal antian-
drogen with a well-known history of human hepatotoxicity
(Wysowski and Fourcroy, 1996)) resulted in a metabolic proﬁle
with conﬁrmed matches to database patterns corresponding to
adrenal steroid synthesis inhibition and antiandrogen receptor
antagonist (Fig. 2) consistent with its pharmacological mode of
action (Rouquie et al., 2009). However, ﬂutamide treatment also
resulted in a number of conﬁrmed matches to MoA patterns
corresponding to various modes of liver toxicity, including liver
toxicity, paracetamol-like toxicity, and cholestasis. These patterns
represent distinct, but somewhat overlapping, metabolite proﬁles
associated with treatments producing liver pathology.
Propylthiouracil at the high dose produced a metabolic proﬁle
that matched MoA patterns indicating a direct effect on the thyroid
(Fig. 3), entirely consistent with this drug’s pharmacological action
(Ma et al., 2007). While the MetaMap1Tox database lacks MoA
patterns for anti-retroviral pharmacology, it did have MoA pattern
matches for the metabolite proﬁle elicited by high dose zidovudineFig. 3. Ranking of patterns matching the metabolite changes induced by propylthiourac
reader is referred to the web version of this article.)
See legend for Fig. 2.treatment. These included MoAs for platelet and adrenal effects
and kidney toxicity, effects (Fig. 4), documented in literature
reports (Omar et al., 1996; Ragni et al., 1992; Tortorella et al., 2009),
as well as MoAs associated with bone marrow suppression; this
toxicity is well known for this drug (D’Andrea et al., 2008).
Relevant to this investigation however, both propylthiouracil and
zidovudine treatments produced metabolite proﬁles that matched
MoA patterns associated with liver toxicity (Figs. 3 and 4,
respectively), such as liver oxidative stress for propylthiouracil
and and liver enzyme induction as well as paracetamol-like
toxicity for zidovudine. And while the in vivo ﬁndings for rats
treated with these compounds showed little evidence of hepato-
toxicity, human hepatoxicity for both compounds has been
well-established (Chen et al., 1992; Russo et al., 2004).
By contrast, treatment with vancomycin or lamivudine (Figs. 5
and 6, respectively) produced metabolite proﬁles that matched
only a small number of MoA patterns associated with toxicity, none
being associated with liver toxicity. While vancomycin treatment
has not been associated with anemia (as might be expected by
porphyrin inhibiton), lamivudine treatment has been associatedil treatment. (For interpretation of the references to color in this ﬁgure legend, the
Fig. 4. Ranking of patterns matching the metabolite changes induced by zidovudine treatment. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
See legend for Fig. 2.
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gonadotropin-releasing hormone (GnRH) agonism (Choi and Lee,
2011). Atropine treatment did result in a metabolite proﬁle that
had matches to patterns of kidney and bone marrow toxicity, as
well as liver toxicity and liver enzyme induction (Fig. 7), but liver
enzyme induction is generally viewed as a compensatory and not
adverse response. None of these adverse effects have been
reported for atropine, but it is conceivable that the CNS effects
of this drug may overshadow any conventional measures of these
toxicities.
Methotrexate treatment, while affecting both body weight and
food consumption (Table 2), elicited a metabolite proﬁle that only
matched a pattern for kidney tubular necrosis (Supporting Fig. 1),
an adverse effect well known for this drug (Widemann and
Adamson, 2006). On the other hand, the low dose treatment with
captopril elicited a metabolite proﬁle with numerous matches to
patterns associated with kidney, bone marrow and liver toxicity
(Supporting Fig. 2). All of these toxicities have been described for
captopril (Andrade et al., 2006; Hoitsma et al., 1991; Pillans and
Koopowitz, 1991) and the metabolite proﬁle for the high dose
captopril treatment was used to establish the pattern for kidney
tubular defects. It should be noted that while the signals for bone
marrow suppression and kidney toxicity are seen at both dose
levels (data not shown) and clinical pathology effects were
observed only at the high dose, the patterns for liver toxicities
only matched the metabolite proﬁle elicited by low dose captopril
treatment (Supporting Fig. 2). Such an “inverse” dose response has
been seen for other effects of captopril, namely the effect of this
drug on water drinking where captopril enhanced drinking at low
doses but inhibited it at high doses (Evered and Robinson, 1984).However, a mechanistic basis for such an inverse response in either
case is speculative at this point.
Treatment of rats with the anti-depressant nefazodone elicited
a metabolic proﬁle that matched a MoA pattern associated with
adrenal steroid synthesis Inhibition (Supporting Fig. 3); this drug
has been reported to indeed have an effect on the hypothalamic–
pituitary–adrenal axis in rats (Matheson et al., 1997). Both
nefazodone and nevirapine treatment elicited metabolic proﬁles
that matched MoA patterns for various liver toxicities (Supporting
Figs. 3 and 4), including paracetamol-like hepatotoxicity (both
drugs) and peroxisome proliferation (nevirapine). And while
neither drug treatment resulted in in vivo signs of hepatoxicity
(Table 2), both drugs are associated with human liver injury
(Chu et al., 2010; Stewart, 2002); nefazodone was withdrawn from
the market due to its risk (Edwards, 2003).
Valproic acid treatment at the high dose yielded a metabolic
proﬁle that matched an MoA pattern for adrenals steroid synthesis
Inhibition (Supporting Fig. 5), as might be expected given this
compound’s inhibition of steroid hormone metabolism (Morrell,
2003). However, there were also matches to multiple MoA patterns
for peroxisome proliferation, a liver pathology. The relationship of
this rodent pathology to human pathologies is not clear, as
multiple receptors can be activated by the same compound.
Nonetheless, valproic acid is well known to be capable of causing
human hepatoxicity.
Treatment with neomycin sulfate produced a plasma metab-
olome that could be matched to MoA patterns for kidney tubular
necrosis, bone marrow suppression, and liver enzyme induction
(Supporting Fig. 6). While kidney toxicity is recognized for system
neomycin exposure (Masur et al., 1976), and bone marrow effects
Fig. 5. Ranking of patterns matching the metabolite changes induced by vancomycin treatment. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
See legend for Fig. 2.
474 W. Mattes et al. / Toxicology Letters 230 (2014) 467–478have been seen in dogs treated intramuscularly (Nelson et al.,
1951), there are no reports of liver enzyme induction or toxicity.
Treatment of rats with either mannitol or streptomycin sulfate,
while resulting in modest in vivo effects (Table 2), produced
metabolite proﬁles that lacked matches to established MoA
patterns (Supporting Figs. 7 and 8, respectively).
As noted in Section 2.4, and as can been seen in the pattern
ranking displays, several speciﬁc patterns may be associated with a
general mechanism of toxicity, such as cholestasis or paracetamol-
type toxicity. Hence, for each compound treatment, the numbers of
such common patterns can be summed. For example, the
metabolite proﬁle induced by high-dose phenytoin treatment
matched the MoA proﬁles of “Liver_toxicity_female high dose” and
“Liver_toxicity_male high dose” (data taken from reference (Kamp
et al., 2012)). Based on the type of pathology associated with these
MoAs, both of these MoA patterns can be considered “Liver, cell
damage” and were counted as two matches to this common MoA.
Such an analysis of common patterns of liver toxicity is presented
in Table 3 and Fig. 8. Of course, any given general mechanism of
toxicity may have more patterns associated with it than another, so
that a greater count of pattern matches would not necessarily
equate to a greater degree of hepatotoxic potential. Nevertheless,
the results do indicate that with the exception of methotrexate,
those compounds with clear literature evidence for human DILI do
produce metabolic proﬁles that contain matches for metabolite
patterns associated with hepatotoxicity. By contrast, of the six
compounds lacking clear literature evidence for human DILI, only
atropine produced metabolic proﬁles that contained matches for
one metabolite proﬁle associated with hepatotoxicity. As notedearlier, it is conceivable that the CNS effects of this drug may
overshadow any conventional measures of liver toxicity.
4. Discussion
Exposure of any cell or organism to a toxicant leads to a cascade
of events that may or may not lead to overt toxicity as evinced by
organ failure or death. As Gregus has noted (Gregus, 2008), several
steps must take place for an adverse outcome (Fig.1). The molecule
must ﬁrst be absorbed into the system, after which it may be bio-
transformed into a molecule with either greater or lesser toxicity.
The parent or transformed molecule may then be excreted,
removing it from the biological system, or delivered to a target site.
At the target site the parent toxicant or its metabolite may either
interact with a target molecule or alter the biological environment
to produced cellular dysfunction or injury. The toxicant may also
interact with multiple targets to effect toxicity, as is seen for
gastrointestinal injury induced by nonsteroidal anti-inﬂammatory
drugs (Boelsterli et al., 2013). At this point, repair or adaptation
may take place so as to return the biological system to
homeostasis, or such processes may lead to toxicity instead of
repair. Importantly, biochemical changes occur at every step in this
cascade (Fig. 1).
Previous reports have described a mass spectrometry-based
approach to metabolite proﬁling, wherein all individual metab-
olites are identiﬁed in a given sample (van Ravenzwaay et al.,
2007). Coupled with a reference database of metabolite proﬁles
(MetaMap1Tox) (van Ravenzwaay et al., 2012), where patterns
associated with known mechanisms of toxic and pharmacologic
Fig. 6. Ranking of patterns matching the metabolite changes induced by lamivudine treatment. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
See legend for Fig. 2.
W. Mattes et al. / Toxicology Letters 230 (2014) 467–478 475action (MoAs) have been elucidated, this approach allows for the
detection of MoAs following treatment with a novel compound.
Exploring the possibility that biochemical changes may indeed
represent parameters responsive to events early in the develop-
ment of toxicity, previous studies examined whether metabolite
proﬁling may indicate signals of toxicity in the absence of signals
from conventional parameters (Kamp et al., 2012; Mattes et al.,
2013). As a clear example, MoA’s indicative of hepatotoxicity were
detected in the metabolite proﬁles of rats treated with doxorubicin
at doses that did not elicit signals from conventional parameters of
liver injury. The current study extended the question of enhanced
signal detection with metabolomics to compounds known to
produce toxicity (hepatotoxicity) in humans, but not reported to do
so in rats.
Under the conditions of this current study, treatment of rats
with compounds clearly associated with human DILI generally
resulted in plasma metabolite proﬁles that, when queried against
the MetaMap1Tox database, matched metabolite patterns associ-
ated with mechanisms of hepatotoxicity. By contrast, treatment of
rats with compounds not associated with human DILI generally
resulted in plasma metabolite proﬁles that, when queried against
the MetaMap1Toxdatabase, did not match metabolite patterns
associated with mechanisms of hepatotoxicity. In this study, 8 of 9
DILI-positive compounds were correctly identiﬁed; 5 of 6 DILI-
negative compounds were correctly identiﬁed as such, giving an
overall sensitivity and speciﬁcity of 89% and 83%, respectively
(albeit the total number of compounds examined is rather small).
That hepatotoxicity is a multi-step process, involving pathways
of both damage and repair, is well accepted. Indeed, the stochasticnature of disease and/or toxicity (Coggon and Martyn, 2005)
suggests that any given treatment or stimulus is unlikely to always
result in the terminal response culminating a multistep process.
What is known is that not all drugs have the potential for eliciting
human DILI even in large populations. The results presented in this
paper suggest that treatment of rats with compounds that do have
the potential for human DILI creates an initial event with a clear
metabolic response consistent with a multi-step process (Fig. 1).
The subsequent steps that would lead to DILI in a clinical situation
are either lacking in the rat model or abrogated by repair pathways
in the healthy rat that allow it to recover and return to homeostasis
from the initial insult (Fig. 1) without showing clinical or
histopathology signals. Nonetheless, the essential characteristic
of a compound with DILI-potential, i.e., the initiating event, is
present at some level in the preclinical studies we evaluated and
are detectable by changes in the overall metabolome in blood.
The exact molecular pathway connecting any observed DILI
pathology with an initiating event has yet to be determined. One
can only speculate as to how such a pathway may differ between
humans and rats in the case where the drug-induced pathology is
seen in humans but not in rats. A clear difference between the
human situation as compared to the rat model is that polymor-
phisms in e.g., drug metabolism occur with much higher impact in
humans as compared to the commercially bread rat strain used in
this study. It would seem equally speculative to compare drug-
induced pathologies seen in the clinic for the compounds
described here with the MoAs matching the metabolite proﬁle
elicited by those compounds in treated rats, which themselves are
not displaying those pathologies. Nonetheless, it is intriguing to
Fig. 7. Ranking of patterns matching the metabolite changes induced by atropine treatment. (For interpretation of the references to color in this ﬁgure legend, the reader is
referred to the web version of this article.)
See legend for Fig. 2.
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known for mixed hepatocellular and cholestatic injury in humans
(Zimmerman, 1999), produced metabolite proﬁles that matched
liver MoA patterns corresponding to “cell damage” “cholestasis”,
and “paracetamol-like toxicity.” Zidovudine treatment, clinically
known for hepatocellular damage (Zimmerman, 1999), produced a
metabolite proﬁle that matched “paracetamol-like toxicity.” On
the other hand, propylthiouracil treatment, clinically known for
hepatocellular damage (Zimmerman, 1999), matched MoAs of
“peroxisome proliferation” and “oxidative stress”; captopril
treatment, clinically know for mixed hepatocellular–cholestaticTable 3
Count of patterns mapping to a given toxicity MoA for the test compounds.
Clear literature evidence of clinical DILI
Toxicity MoA Phenytoin Flutamide PTU Methotrex
Liver, cell damage 2 1 0 0 
Liver, cholestasis 2 3 0 0 
Liver, paracetamol-like toxicity 1 1 0 0 
Liver, peroxisome proliferation 0 0 1 0 
Liver, oxidative stress 0 0 2 0 
Grand total 5 5 3 0 
No clear literature evidence of clinical DIL
Toxicity MoA Atropine Mannitol N
Liver, cell damage 1 0 0
Liver, cholestasis 0 0 0
Liver, paracetamol-like toxicity 0 0 0
Liver, peroxisome proliferation 0 0 0
Liver, oxidative stress 0 0 0
Grand total 1 0 0damage, matched the MoA of “oxidative stress”; and valproic acid
treatment, clinically known for hepatocellular damage (Zimmer-
man,1999), matched the MoA of “peroxisome proliferation.” Again,
the metabolite proﬁle may only hint at the molecular pathway and
resulting pathology.
In conclusion, these results show that the MetaMap1Tox
database and associated mechanistic metabolite patterns can
detect signals of hepatotoxicity in rats treated with compounds
under conditions where signals of hepatotoxicity are not seen with
conventional parameters. These compounds include those that
have been reported to elicit overt hepatotoxicity in humans, butate Captopril Nefazodone Nevirapine Valproic Zidovudine
0 0 0 0 0
0 0 0 0 0
0 1 1 0 1
0 0 2 3 0
2 0 0 0 0
2 1 3 3 1
I
eomycin Streptomycin Vancomycin Lamivudine
 0 0 0
 0 0 0
 0 0 0
 0 0 0
 0 0 0
 0 0 0
Fig. 8. Liver-related toxicity MoA pattern matches per compound.
Summary counts of common patterns of liver toxicity for each compound
treatment. High dose treatments were evaluated, except for those of captopril,
where the low dose treatment was evaluated. Abbreviations: PTU: propylthiouracil.
Data taken from Table 3.
W. Mattes et al. / Toxicology Letters 230 (2014) 467–478 477not in rats. The speciﬁc molecular pathways resulting in DILI have
yet to be determined, but the observation that compounds with
DILI potential produce a metabolome response with common
characteristics holds promise for their discovery.Conﬂict of interest
The authors declare that there are no conﬂicts of interest.
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